Anand Mehra
a member of our Board
$1.5 million
November 2024
Purchased 666,666 shares of common stock at $2.25 per share in a private placement.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Neal Walker
Also a director
CEO
Title from the Form 4 dated Feb 3, 2026
|
56 | Not stated | Not stated | $3,375,591 | |
|
Kevin Balthaser
Chief Financial Officer
|
39 |
Since 2023
3 years
|
2017 | $1,490,790 | |
|
Hugh Davis, Ph.D.
Also a director
President and COO
Title from the Form 4 dated Feb 3, 2026
|
67 | Not stated | Not stated | Not reported | |
|
Jesse Hall
Chief Medical Officer
|
52 |
Since 2025
1 year
|
Not stated | Not reported | |
|
Roland Kolbeck
Chief Scientific Officer
|
62 |
Since 2025
1 year
|
Not stated | Not reported | |
|
James Loerop
Chief Business Officer
|
62 |
Since 2022
4 years
|
Not stated | $1,447,106 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased 666,666 shares of common stock at $2.25 per share in a private placement.
Loading...